Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  (A*STAR) The use of digitised proteomic mapping using mass spectrometry to identify optimal conditions for biological therapy products


   Faculty of Biology, Medicine and Health

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Prof Anthony Whetton, Dr Richard Unwin  No more applications being accepted  Competition Funded PhD Project (European/UK Students Only)

About the Project

Biological therapies (such as antibodies) are revolutionising precision medicine. We need more such products and better quality products. Generally these antibodies are produced by engineered cell lines. We will develop enhanced conditions to produce these biological therapies. We will then use advanced mass spectrometry/proteomics to develop a real time readout of cultures that is based in the expertise developed in the Stoller Biomarker Discovery Centre, the largest clinical proteomics centre in the world.
This studentship offers a combination of real world experience in biological therapy manufacturing with an excellent training in mass spectrometry, an area where there is a major skills shortage. We will also provide training in informatics for mass spectrometry and proteomics.

Entry Requirements:
Applications should be submitted online and candidates should make direct contact with the Manchester supervisor to discuss their application directly. Applicants must have obtained, or be about to obtain, at least an upper second class honours degree (or equivalent) in a relevant subject.

Funding Notes

This project is available to UK/EU candidates. Funding covers fees (UK/EU rate) and stipend for four years. Overseas candidates can apply providing they can pay the difference in fees and are from an eligible country. Candidates will be required to split their time between Manchester and Singapore, as outlined on www.manchester.ac.uk/singaporeastar.

As an equal opportunities institution we welcome applicants from all sections of the community regardless of gender, ethnicity, disability, sexual orientation and transgender status. All appointments are made on merit.

References

1. Pearson, S., Guo, B., Azadbakht, N., Brazzatti, J., Patassini, S., Mulero-Navarro, S., Flotho, C., Gelb, B. D., Whetton, A. D., Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia. Journal of Proteome Research. 2019 Oct. doi: 10.1021/acs.jproteome.9b00495
2. Geary, B., Walker, M.J., Snow, J.T., Lee, D.C.H., Pernemalm, M., Maleki-Dizaji, S., Azadbakht, N., Apostolidou, S., Barnes, J., Krysiak, P., Shah, R., Booton, R., Dive, C., Crosbie, P.A., Whetton, A. D. Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients. Journal of Proteome Research. Sep 2019; 18(9), pp.3369-3382. doi: 10.1021/acs.jproteome.9b00287
3. Alanazi, B., Munje, C.R., Rastogi, N., Williamson, A.J.K., Taylor, S., Hole, P.S., Hodges, M., Doyle, M., Baker, S., Gilkes, A.F., Knapper, S., Pierce, A., Whetton, A. D., Darley, R.L., Tonks, A. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia. In Press
4. Abraham SA, Hopcroft LEM, Carrick E, Drotar M, Dunn K, Williamson AJK, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD and Holyoake TL (2016) Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 2016 Jun 16;534 (7607):341-6. doi: 10.1038/nature18288
5. Banu M, Ng D, Zheng L, Goh L-T, Bi X, Siak-WeiOw D, (2014) Rapid quantification of Escherichia coli in food and media using bacteriophage T7 amplification and liquid chromatography-multiple reaction monitoring tandem mass spectrometry Journal of Biotechnology doi.org/10.1016/j.jbiotec.2014.10.017